DFTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Definium Therapeutics Inc (DFTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The strong analyst ratings, significant price target increases, and promising Phase IIb trial results for DT120 suggest a high potential for growth. While the stock has experienced a recent price drop, this could present an attractive entry point for long-term investors.
The stock closed at $16.29, down 6.46% during the regular market session. However, it showed a slight recovery in post-market trading with a 0.37% increase. The pre-market change of 0.06% indicates minimal volatility. No significant trading trends from hedge funds or insiders were observed.
Strong analyst ratings with multiple price target increases (Jefferies: $30, Baird: $37, RBC Capital: $36).
Promising Phase IIb trial results for DT120 with a 48% remission rate in generalized anxiety disorder.
Anticipation of two Phase III trials for DT120 starting in Q2 2026.
Recent 6.46% drop in regular market trading.
Lack of revenue growth and negative net income in the latest financial quarter.
In 2025/Q3, the company reported no revenue growth (0% YoY), but net income improved significantly by 391.56% YoY to -$67.27M. EPS also improved by 333.33% YoY to -$0.78. Gross margin remained at 0%. While the company is not yet profitable, the financials show signs of improvement.
Analysts are highly optimistic about DFTX. Jefferies initiated coverage with a Buy rating and a $30 price target, citing confidence in DT120's efficacy. Baird raised its price target to $37, and RBC Capital increased its target to $36, highlighting long-term sales potential for DT120.
